Thông tin cho nhân viên y tế
Thuốc mới và thông tin từ Drugs.com
- NOVATO, Calif., August 19, 2026 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Genglycos™ (pariglasgene brecaparvovec-opnr)…
- TARRYTOWN, N.Y., August 19, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new…
- CINCINNATI–(BUSINESS WIRE)–LIB Therapeutics, Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their cholesterol goals, today announced the U.S. Food and Drug Administration (FDA)…
- BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and…
- PRINCETON, N.J.–(BUSINESS WIRE)–August 13, 2026 Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and…
- WOBURN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration…
- THURSDAY, Aug. 20, 2026 — The Composite Dietary Antioxidant Index (CDAI) is significantly inversely associated with cervical cancer (CC) prevalence, according to a study published online Aug. 19 in the International Journal of Gynecology &…
- THURSDAY, Aug. 20, 2026 — The global health workforce has expanded since 1990, mainly due to an increase in female health workers, according to a study published online Aug. 18 in The Lancet Public Health.Megan Knight, from the Institute for…
- THURSDAY, Aug. 20, 2026 — Childhood-onset epilepsy is associated with significantly lower completion rates of primary school and long-term educational attainment, according to a study published online Aug. 18 in the Journal of Neurology…
- THURSDAY, Aug. 20, 2026 — The timeliness of the transition from emergency department (ED) to inpatient management varies considerably by hospital, according to a research letter published online in the Journal of the American Medical…
- THURSDAY, Aug. 20, 2026 — Laser interstitial thermal therapy (LITT) shows promise for patients with primary and metastatic brain tumors, with short hospital stays and preserved quality of life, according to a study published online Aug. 17 in the…
- THURSDAY, Aug. 20, 2026 — Sleep disturbances and long sleep duration are associated with a reduction in working life expectancy (WLE), according to a study published online Aug. 18 in Occupational & Environmental Medicine.Saana Myllyntausta…
Thông tin từ The Pharma Letter
- UroGen Pharma, a US biotech focused on treating urothelial and specialty cancers, has entered into a strategic option and research license agreement and a related equity investment agreement with IntraGel Therapeutics.
- Aurora Cannabis, a Canada-based global medical cannabis company, announced that it has acquired Internode Pharma Limited, a licensed importer and wholesaler, and HAP Pharma Limited, a licensed pharmacy.
- Danish clinical-stage techbio Evaxion, which is pioneering AI-Immunology platform, today provided business update and second quarter 2026 results.
- New data published by the UK’s National Health Service (NHS) Business Services Authority (NHSBSA) provides insights into prescribing for diabetes in England, including trends in prescription volumes, costs and the types of medicines prescribed.
- Indian pharma major Lupin announced Thursday that its wholly-owned subsidiary VISUfarma has entered an exclusive licensing agreement.
- The US Food and Drug Administration (FDA) has granted approval for Regeneron Pharmaceuticals’ Pasatru (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP).
Thông tin từ BioPharmaDive
- Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
- Moderna gained $45 billion in market value in a single day, a surge that brought the company’s stock to levels not seen since 2024 — and saddled it with expectations that may be tough to meet.
- The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an eagerly anticipated study readout.
- Heidi Overton, a medical doctor and veteran of the America First think tank, currently serves as deputy director of the White House Domestic Policy Council.
- At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.
- The Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.
Thông tin từ STAT News
- What you need to know about Heidi Overton, and Erica Schwartz's first speech to CDC staff.
- Regeneron wins ultra-rare disease drug approval, a validating win for mRNA research, and more biotech news from The Readout
- Heidi Overton's rise under Trump, inside a 5-year-old brain organoid, and other health news from Morning Rounds
- A Regeneron drug for an ultra-rare disease that causes bone to grow where it shouldn't won U.S. regulatory approval, capping a three-decade effort
- Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.
- Between success with a pancreatic cancer drug and now success with an mRNA neoantigen vaccine, it has been a banner year for developing cancer therapies.
Thông tin từ Nature Review Drug Discovery
- Nature Reviews Drug Discovery, Published online: 12 August 2026; doi:10.1038/d41573-026-00136-zOncolytic virus nabs FDA approval
- Nature Reviews Drug Discovery, Published online: 10 August 2026; doi:10.1038/d41573-026-00135-0As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists.
- Nature Reviews Drug Discovery, Published online: 07 August 2026; doi:10.1038/s41573-026-01496-2Applications of artificial intelligence (AI) in drug discovery have attracted high interest in recent years, but evidence for clinically relevant impact so far is limited. This Perspective discusses potential reasons, including an insufficient focus on clinical translation during model development and difficulties with applying AI algorithms […]
- Nature Reviews Drug Discovery, Published online: 06 August 2026; doi:10.1038/d41573-026-00133-2First dual BAFF and APRIL inhibitor nabs FDA approval
- Nature Reviews Drug Discovery, Published online: 06 August 2026; doi:10.1038/d41573-026-00134-1Lilly spends US$2.8 billion on psychedelic drugs for mental health
- Nature Reviews Drug Discovery, Published online: 05 August 2026; doi:10.1038/d41573-026-00132-3Expanding the molecular glue target space